comparemela.com
Home
Live Updates
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved ... : comparemela.com
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved ...
CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023)60% decreased risk of long-term all-cause mortality (>18
Related Keywords
Salt Lake City ,
Utah ,
United States ,
Massachusetts ,
Maryland ,
Benjamin Greenberg ,
Jamesd Berry ,
Seanm Healey ,
Motor Neuron Disorder Division ,
Linkedin ,
Nasdaq ,
Neurology Department ,
Twitter ,
Securities Exchange ,
Clene Inc ,
Clene Nanomedicine Inc ,
Neurological Clinical Research Institute At Massachusetts ,
Analysis Validates Association Of Nf ,
Term Plasma Nfl Biomarker Findings ,
Trial Open Label Extension ,
Mixed Model ,
Repeat Measures ,
Least Squared Means ,
Natural Log ,
Associate Professor ,
Neurological Clinical Research Institute ,
Massachusetts General Hospital ,
Term Survival Improvement ,
Chair Neurology Department ,
Mass General Hospital ,
Julianne Dorn Professor ,
Neurology Harvard Medical School ,
Principal Investigator ,
Analysis Validates Association ,
Clinical Morbidity Outcomes ,
High Risk ,
Clene Nanomedicine ,
Open Label Extension ,
Combined Assessment ,
Securities Exchange Act ,
Securities Act ,
Annual Report ,
Quarterly Reports ,
Region ,
comparemela.com © 2020. All Rights Reserved.